Navigation Links
Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results

WALTHAM, Mass., March 20 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), announced today that it will host a conference call and webcast on Thursday, March 27, 2008 at 4:30 p.m. EDT to review the Company's fourth quarter and year end 2007 financial results and provide an update on recent corporate developments.

To access the live call, dial 877-440-5803 (domestic) or 719-325-4900 (international). The live webcast will be available in the Investors section of the Company's website,

Replay access of the teleconference will be available for two weeks following the call by dialing 719-457-0820 (domestic) or 888-203-1112 (international). The passcode for the replay is 3385694. The webcast will be archived following the call at

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Retains Top Life Science Communications Firms
2. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
3. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
4. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
5. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
6. Interleukin Genetics Announces Management and Board Appointments
7. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
8. deCODE Genetics Announces Full-year 2007 Financial Results
9. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
10. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
11. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
Post Your Comments:
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... November 25, 2015 , ... A ... Black Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum ... met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
Breaking Biology Technology:
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... 29, 2015 NXTD ) ... focused on the growing mobile commerce market and ... StackCommerce, a leading marketplace to discover and buy ... smart wallet on StackSocial for this holiday season. ... the "Company"), a biometric authentication company focused on ...
Breaking Biology News(10 mins):